“Once 2-73 is approved and the full AD data is published, the disease mechanism proposed by Anavex will be taken far more seriously.”
I’d change it to “if 2-73 is approved…”
But your point is valid. And part of the upside is that Anavex will become, overnight, the leader in Sigma-1 knowledge and that will make the company very appealing if others decide maybe there’s something to the upstream MOA.
Market Data 
Markets 
AI
